The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Pooled in vivo and in vitro CRISPR-Cas9 based screening have nominated several tumour intrinsic drivers of resistance to immunotherapy 4,8-11 , but therapeutic applications of these findings remain limited.”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“thus it is surprising that TBK1 has been nominated as a candidate immune evasion gene 4,9-11”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“CRISPR/Cas9 KO screens in murine models or engineered human cell lines testing tumor-T cell interactions identified putative novel mechanisms of immune evasion involving chromatin regulators10, TNFα signaling11, SOX412, PTPN213, and APLNR10, yet their clinical relevance is unclear.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“consistent with prior reports12, induction of CD49f, which encodes an integrin associated with epithelial-to-mesenchymal transition (EMT).”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“In previous screens, antigen-specific T cells targeting model tumor associated antigen (TAA), such as OVA, gp100, and NY-ESO-1, were used (Manguso et al., 2017; Pan et al., 2018; Patel et al., 2017).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Pan et al., 2018
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationTrapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–857 of 857
Zhou, X., Yan, Z., Yang, J., Tang, J., Cen, W.-C., Cui, J., Teng, W., Ling, Y., Long, N., Guo, Z., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110859
Polybromo-1 Bromodomain Inhibitor Selectivity Is Mediated by a Unique Ligand-Binding Pocket
Nuñez, R., Bursch, K. L., Makowski, S. J., Xue, M., Cozzolino, K., Shishodia, S., Keyes, R. F., Zhu, N., & Smith, B. C. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00352
Checkpoint Blockade in Hematologic Malignancies
Charalambous, A., & Schwarzbich, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_178
Immunotherapy for Primary Cancers of Central Nervous System
Maroufi, S. F., Mohammadi, E., Namvar, M., Iranmehr, A., Rezaei, N., & Hanaei, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_240
Transcription factor Zfx regulates tumor’s evasion to T cell killing in immunotherapy
Kaufmann, U., Wang, J., Callow, M. G., Fortin, J., Myrta, S., Nickles, D., Reja, R., Cheng, E., Wonder, E. L., Haley, B., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113842
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8 + TILPreprint
Xie, H., Jiang, A., Dey, A., Dean, J. W., Perera, J., Smith, N. P., Chen, A. C. Y., Anderson, S., Cicerchia, A. M., Sun, Y. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.19.689204
Liu, Y., Lv, G., Bai, J., Song, L., Ding, E. C., Liu, L., Tian, Y., Chen, Q., Li, K., Liu, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19619513
Self-citationZhang, Z., Wang, Z.-X., Chen, Y.-X., Wu, H.-X., Yin, L., Zhao, Q., Luo, H.-Y., Zeng, Z., Qiu, M., & Xu, R.-H. (2022) · Figshare · doi:10.6084/m9.figshare.19687417
Dong, Z., Chong, W., Chen, C., Qi, L., Mengke, L., Dou, M., Jiawei, Y., Longxi, Q., Liu, H., Liu, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26688293
Li, X., Xiong, F., Hu, Z., Tao, Q., Yang, Y., Qiao, X., Peng, C., Jiang, Y., Han, M., Dong, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26671149
Li, X., Xiong, F., Hu, Z., Tao, Q., Yang, Y., Qiao, X., Peng, C., Jiang, Y., Han, M., Dong, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26671152
Cui, Y., Li, J., Zhang, P., Yin, D., Wang, Z., Dai, J., Wang, W., Zhang, E., & Guo, R. (2023) · Figshare · doi:10.6084/m9.figshare.23499401
Courtet, K., Laizet, Y., Lucchesi, C., Bessede, A., & Italiano, A. (2020) · Figshare · doi:10.6084/m9.figshare.12668012
Chen, J., Zuo, Z., Gao, Y., Yao, X., Guan, P., Wang, Y., Li, Z., Liu, Z., Hong, J. H., Deng, P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22598591
Zhang, Z., Wang, Z.-X., Chen, Y.-X., Wu, H.-X., Yin, L., Zhao, Q., Luo, H.-Y., Zeng, Z.-L., Qiu, M., & Xu, R.-H. (2022) · Figshare · doi:10.6084/m9.figshare.19687414
Bao, R., Stapor, D., & Luke, J. J. (2020) · Figshare · doi:10.6084/m9.figshare.13147225
Chen, D., Liu, P., Lu, X., Li, J., Qi, D., Zang, L., Lin, J., Liu, Y., Zhai, S., Fu, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25698270
Zorea, J., Motro, Y., Mazor, R. D., Carmi, Y. K., Shulman, Z., Mahajna, J. A., Moran-Gilad, J., & Elkabets, M. (2024) · Figshare · doi:10.6084/m9.figshare.26586060
Chen, D., Liu, P., Lu, X., Li, J., Qi, D., Zang, L., Lin, J., Liu, Y., Zhai, S., Fu, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25698385
Song, Y., Zhong, C., Huang, J., Shuai, W., Hu, X., Bian, Y., He, Q., & Li, Y. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003591
Gentile, C., Feng, W. W., Lenahan, S. M., Ying, A. W., Card, D. C., Wu, F. T. H., Pham, N., Radulovich, N., Cao, P. M., Hueniken, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.27.708377
Tang, Z., Chi, H., Zhao, W., Wang, R., Yang, Y., Xu, Z., Ding, Z., Chen, K., Lu, J., Hu, S., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04780-0
Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma
Xu, S., Gong, R., Liu, S., Wang, J., Shen, Y., Peng, C., Feng, Q., Luo, M., Lan, F., Fan, J., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03744-6
Li, B., Wei, P., Xie, B., Zhong, X., Wang, X., Lou, X., Zhang, T., & Dong, C. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218464 · Cited by 1
Leruste, A. (2019) · theses.fr (ABES) · doi:10.70675/82d84ef4z7a2cz4ebfzab33z0b80c30ee72d
RNAi and Chemical-Based High Content Screening for the Normalization of XPC Phenotyope
Kobaisi, F. (2021) · theses.fr (ABES) · doi:10.70675/e34b8c43z081az4c41zad64z8e0c753e5c20
Single cell multi-OMICS analysis of Treg biology in cancer
Richer, W. (2021) · theses.fr (ABES) · doi:10.70675/97f429e9z2993z4b78z88dezf46fae0d3a30
Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy
Ma, F., Li, Y., Xiang, C., Wang, B., Lv, J., Shang, Z., Zhang, W., Qin, Z., Pu, Y., Li, K., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00413-9
Liu, J., Qin, J., Shi, X., Liu, Q., Cheng, X., & Zhou, Y. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70200
Inducible, split base editors for in vivo cancer functional genomics
Ren, D., Wang, S., Yamada, K., Liu, Y., Hapke, R., Alpsoy, A., Ho, Y., Zhang, C., Lan, Y., Zhang, S., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03077-5 · Cited by 1
Liu, L., Chen, S., Ding, M., Duan, Y., Pu, L., Li, L., Peng, H., & Yu, Q. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1787786
Cancer immunotherapy: Pros, cons, and beyond
Natarajan, K., Natarajan, K., Rajaram, G., Arulsamy, S., & Babu, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00007-2
Liu, L., Tang, B., Ma, F., Wang, H., Chen, B., Zhang, N., Liu, X., Lyu, Y., & Dong, D. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/6800480
Self-citationLiu, J., Jiang, W., Wang, X., Azoitei, A., Liu, H., Najjar, G., Liu, K., Melzer, M. K., Stilgenbauer, S., Elati, M., et al. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00936-6
Wang, S., Hou, S., Luo, C., Zhang, H., Jin, Y., Zhang, R., Zhao, Y., Xiong, X., Guo, R., Wang, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73241-7
Self-citationWang, Z., Liu, H. M., Wang, X., Teng, J., Zheng, Z., Zhang, J. I.-X., Xiao, W., Liang, Q., Li, J., Jia, X., et al. (2026) · Advanced Science · doi:10.1002/advs.202515158
Zhang, F.-L., Yang, S., Zhang, Y.-L., Zhao, Q., Yang, W.-X., Andriani, L., Cai, J., Huang, M.-Y., Hu, X., Shao, Z. M., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02679-6 · Cited by 1
Chen, C., Liu, S., Feng, J., Luo, Z., Bi, Y., Huang, Q. C., Zhang, Y., Yu, H., Wu, J., Yu, H., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116141
Guo, S., Shi, P., Yang, C., Qian, S., Yang, F., Yin, X., & Sun, B. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154180
Zhang, J., Miao, N., Guo, Y., Liu, Y., Zhou, Y., Zeng, X., & Huang, D. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218763
Zhong, Y., Ren, G., Huang, T., Sang, Y., & Zhang, J. (2026) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-026-10470-y
Botta, G. P., Edwards, W. F., Nishizaki, D., Hargreaves, D. C., Kato, S., & Kurzrock, R. (2026) · iScience · doi:10.1016/j.isci.2026.116772
Luo, C., Xia, N., Hui, S. Y., Wong, U. S., Tsang, J. Y., Hu, H., Tsang, C. M., Lo, K. W., Sun, P., Shao, M., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02763-x
Cai, S., Tan, Y., Yang, Q., & Huang, J. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1878460
Zhang, X., 杜来玲, Tian, K., Chen, L., & Li, X. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1909580
Yang, Z., Tian, Z., Liang, R., Lu, Y., Zhu, T., Wang, Y., & Zhang, W. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71290
Pan-tumor spatial transcriptomics reveals conserved properties of tumor organization
Behera, V., Guzzetta, A., Giba, H., Pen, U.-Y., Lello, A. D., Pandey, B., Doran, B. A., Esposito, A., Pezeshk, A., Husain, A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103013
Epigenetic and metabolic plasticity of tumor cells in immunotherapy resistance
Choi, J.-E., & Baek, I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1968997
Duan, Y., Jiao, L., Liu, P., Duan, C.-H., Li, X., Zhang, Z., Zhang, Y., Ouyang, X., Du, H., Liu, S., et al. (2026) · Advanced Science · doi:10.1002/advs.78086
Chen, L., Cheng, J., & Mao, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1984645
Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions
Ren, Y., Yang, L., Fei, B., Guo, R., Huang, J., Xu, Z., Wang, R., Zhang, P., Cao, D., Chen, P., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3356-1
Self-citationBindingDB Entry 50018757: PROTACs: New method to degrade transcription regulating proteins.
BindingDB (2024) · UC San Diego · doi:10.7270/q2280cvr
Metadata
- Authors
- Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., Long, H. W., Yuan, G.-C., Doench, J., Brown, M., Liu, X. S., & Wucherpfennig, K. W.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Astellas Pharma (Japan) (JP)
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Harvard University (US)
- Corresponding author
- Pan, Deng
- Kobayashi, Aya
- Jiang, Peng
- Liu, X. Shirley
- Wucherpfennig, Kai W.
- ORCID
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 770-775
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5953516
- OpenAlex
- W2782124401
- Cited by
- 852
- References
- 51
- Citations by year
- 2026: 39 · 2025: 96 · 2024: 92 · 2023: 107 · 2022: 123 · 2021: 117 · 2020: 143 · 2019: 86 · 2018: 47
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01CA173750)
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- SWI/SNF complex, PBRM1, immune checkpoint inhibitors, T cell-mediated killing, antitumor immunity, interferon-gamma, renal cell carcinoma, chromatin regulation
- MeSH terms
- CRISPR-Associated Protein 9, Bromodomain Containing Proteins, Animals, Bacterial Proteins, Chromosomal Proteins, Non-Histone, Cytotoxicity, Immunologic, DNA-Binding Proteins, Endonucleases, Genetic Testing, Humans, Immunotherapy, Interferon-gamma, Melanoma, Experimental, Skin Neoplasms, T-Lymphocytes, Cytotoxic, Transcription Factors, HMGB Proteins, Cell Line, Tumor, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
